GreenJay Therapeutics

GreenJay Therapeutics Successfully Completes More than $1 Million in its Seed Round of Financing

Houston, Texas — (June 30, 2023) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a drug formulation company focused on developing safer, more soluble and more efficacious therapies for patients with leukemia and other blood disorders, announced today that the Company has completed its seed round of financing. “We are very pleased with our success …

GreenJay Therapeutics Successfully Completes More than $1 Million in its Seed Round of Financing Read More »

Hodgkin’s Lymphoma

Allogeneic stem cell transplant is a current treatment option for patients with refractory/relapsed classic Hodgkin’s Lymphoma, including those who have failed an autologous transplantation. Hodgkin’s Lymphoma is one of the most curable forms of cancer. The National Cancer Institute reported the five-year Hodgkin’s Lymphoma survival rate was 69.9% in 1975 and 85.4% in 2009. This increase is due …

Hodgkin’s Lymphoma Read More »

Oral Busulfan News

– Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT – Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia Go Back to Publications

Non-Hodgkin’s Lymphoma (NHL)

 High-dose chemotherapy with autologous stem cell transplantation has become standard of care for patients with relapsed aggressive non-Hodgkin’s lymphoma (NHL).  High-dose busulfan, cyclophosphamide and etoposide is an effective regimen resulting in long-term disease-free survival in relapsed malignant lymphoma and prior radiation therapy. The toxicity is moderate with a low treatment-related mortality. NHL patients include diffuse …

Non-Hodgkin’s Lymphoma (NHL) Read More »


Since the early 1990s, chemotherapy followed by an autologous stem cell transplant has been the standard of care for high-risk neuroblastoma, a childhood cancer that starts in nerve cells outside the brain, especially in the tissues of the adrenal glands, and sometimes the neck, chest, or pelvis. Before children receive chemotherapy to destroy the neuroblastoma, …

Neuroblastoma Read More »

Myelodysplastic Syndrome

A Myelodysplastic Syndrome (MDS) is one of a group of cancers in which immature blood cells in the bone marrow do not mature, and as a result, do not develop into healthy blood cells. Some types may develop into acute myeloid leukemia. Risk factors include previous chemotherapy or radiation therapy, exposure to certain chemicals such as tobacco smoke, pesticides, and benzene, and …

Myelodysplastic Syndrome Read More »

Acute Myeloid Leukemia (AML)

Currently, IV busulfan is the gold standard for use as a pre-treatment for stem cell transplantation in AML patients. According to the Center for International Blood and Marrow Transplant Research (CIBMTR), IV busulfan is used in 74% of the patients. Despite the high usage of IV busulfan in this patient population, there are no busulfan …

Acute Myeloid Leukemia (AML) Read More »

Chronic Myeloid Leukemia (CML)

While busulfan is used to treat patients with chronic myeloid leukemia (CML), it has been demonstrated that imatinib, a tyrosine kinase inhibitor (TKI), has become a cost-effective first-line treatment despite chronic side effects observed in many patients. Serious and cumulative toxicity has been observed with tyrosine kinase inhibitors that had been expected to replace imatinib. …

Chronic Myeloid Leukemia (CML) Read More »

Aplastic Anemia

Normally, red blood cell, white blood cell and platelet levels stay within certain ranges. In aplastic anemia all three of these blood cell levels are low.  Treatments for aplastic anemia, which will depend on the severity of your condition and your age, might include observation, blood transfusions, medications, or bone marrow transplantation. Severe aplastic anemia, …

Aplastic Anemia Read More »


Sickle Cell Anemia and Beta Thalassemia Busulfan may be an important component in CRISPR technology as a conditioning agent to remove diseased cells prior to CRISPR gene editing. A new medical breakthrough gives promise to sickle cell anemia and thalassemia patients using CRISPR-Cas 9 technology, a gene editing technology, with IV busulfan as a conditioning …

CRISPR Read More »